$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions

Follows Promising Recent Clinical Data

 
• By Ian Haydock
  
Conceptual image of liver damage as a result of drugs, viruses, toxins, bacteria, parasites, 3D illustration - Illustration
Takeda Builds Liver Disease Interests With Arrowhead Deal • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip